Patents Issued in October 21, 2008
  • Patent number: 7438886
    Abstract: The present application relates to a process for removing hydrogen sulfide H2S from a gas (1) by contacting said gas with a liquid solution (2) containing ferric sulfate in an absorption column (RC). Ferric sulfate and H2S react at room temperature and at a pressure ranging from 1 to 1.2 atm. Ferric ions being reduced to two-valent iron and sulfide oxidised to elemental sulfur. The liquid (4) coming out of the absorption column is filtered in two steps, the retentate (6, 8) comprising elemental sulfur, the filtrate (5, 7) containing the iron ions. The filtrate is sent to a bioreactor (RB) for regeneration, i.e. oxidation of iron to Fe3+ by means of thiobacillus ferroxidans and air injection (10). The regenerated solution is reused in the absorption column (RC). The process faces the problems relating to the alignment between the chemical step and the biological step in order to obtain a process which can stably run continuously.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: October 21, 2008
    Assignee: Enitechnologie S.p.A.
    Inventors: Roberto Gianna, Umberto Barberini, Mario Galileo Valdiserri, Francesco Crescenzi, Andrea Robertiello
  • Patent number: 7438887
    Abstract: Nanowires, films, and membranes comprising ordered porous manganese oxide-based octahedral molecular sieves, and methods of making, are disclosed. A single crystal ultra-long nanowire includes an ordered porous manganese oxide-based octahedral molecular sieve, and has an average length greater than about 10 micrometers and an average diameter of about 5 nanometers to about 100 nanometers. A film comprises a microporous network comprising a plurality of single crystal nanowires in the form of a layer, wherein a plurality of layers is stacked on a surface of a substrate, wherein the nanowires of each layer are substantially axially aligned. A free standing membrane comprises a microporous network comprising a plurality of single crystal nanowires in the form of a layer, wherein a plurality of layers is aggregately stacked, and wherein the nanowires of each layer are substantially axially aligned.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: October 21, 2008
    Assignee: The University of Connecticut
    Inventors: Steven Lawrence Suib, Jikang Yuan
  • Patent number: 7438888
    Abstract: Molybdenum oxide nano-particles. The nano-particles may be made by vaporizing the precursor material to produce a vapor; directing the vapor into an isolation chamber; contacting the vapor contained in the isolation chamber with a quench fluid stream to precipitate nano-particles; and removing the nano-particles from the isolation chamber.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: October 21, 2008
    Assignee: Cyprus Amax Minerals Company
    Inventors: Mohamed H. Khan, James A. Cole, Joel A. Taube
  • Patent number: 7438889
    Abstract: A process for producing hydrogen comprising reacting at least one hydrocarbon and steam in the presence of a complex metal oxide and a steam-hydrocarbon reforming catalyst in a production step under reaction conditions sufficient to form hydrogen and a spent complex metal oxide, wherein the complex metal oxide is represented by the formula (A?xCax?Mgx?)x(B?yMny?Fey?)yOn where A? represents at least one element selected from the group consisting of Sr, Ba, a Group 1 element, and an element of the Lanthanide series according to the IUPAC Periodic Table of the Elements; B? represents at least one element selected from the group consisting of Cu, Ni, Co, Cr, and V; 0?x?1, 0?x??1, 0?x??1 wherein x+x?+x?=x; 0?y?1, 0?y??1, 0?y??1 wherein y+y?+y?=y; 1?x?10; 1?y?10; and n represents a value such that the complex metal oxide is rendered electrically neutral.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: October 21, 2008
    Assignee: University of South Carolina
    Inventors: Guido Peter Pez, Baolong Zhang, Hans-Conrad zur Loye
  • Patent number: 7438890
    Abstract: The present invention provides binding moieties for CEA, which have a variety of uses wherever detecting, isolating or localizing CEA, and particularly CEA as opposed to cross-reactive antigens such as NCA, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding CEA, which is overexpressed in adenocarcinomas of endodermally derived digestive system epithelia and fetal colon. Such polypeptides and disclosed derivatives are useful, e.g., as imaging agents for CEA-expressing tumors.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: October 21, 2008
    Assignee: Dyax Corp.
    Inventors: Isaac J. Rondon, Robert Charles Ladner
  • Patent number: 7438891
    Abstract: The present invention relates in part to a method of imaging cardiovascular plaque formation in a mammal comprising administering to the mammal an effective amount of 18F-2-fluorodeoxy-D-glucose and then detecting the 18F-2-fluorodeoxy-D-glucose.
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: October 21, 2008
    Inventors: David R. Elmaleh, Alan J. Fischman, John Babich
  • Patent number: 7438892
    Abstract: The present invention is directed to novel methods for assaying for modulators of GADD45 polypeptide activity. The invention also provides means to sensitize a proliferating cell to a DNA base-damaging agent by administration of novel inhibitors of GADD45 polypeptide activity. The invention further provides polypeptides which interfere with the ability of Cdc2/cyclin B1 complexes to cause a pause at the G2/M stage of the cell cycle in response to GADD45, and nucleic acids which encode such polypeptides.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: October 21, 2008
    Assignee: The United States of Americas as represented by the Secretary of the Department of Health and Human Services
    Inventors: Xin Wei Wang, Curtis C. Harris, Albert J. Fornace, Jill D. Coursen, Qimin Zhan
  • Patent number: 7438893
    Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: October 21, 2008
    Assignee: Massachusetts General Hospital
    Inventors: David R. Elmaleh, Timothy Shoup, Alan J. Fischman
  • Patent number: 7438894
    Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.
    Type: Grant
    Filed: October 7, 2003
    Date of Patent: October 21, 2008
    Assignee: Mallinckrodt, Inc.
    Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
  • Patent number: 7438895
    Abstract: Precipitated silica comprising porous silica particles having a cumulative surface area for all pores having diameters greater than 500 ? of less than 6 m2/g, as measured by mercury intrusion, and a percentage cetylpyridinium chloride (% CPC) Compatibility of greater than about 85%. The precipitated silica product is especially well-adapted for use in dentifrices containing cetylpyridinium chloride, which do not attach to the low surface area silica product in a meaningful level and thus remain available for antimicrobial action. Processes for making the silica product including the introduction of sodium sulfate powder during different process steps in order to enhance such a compatibility with CPC are provided.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: October 21, 2008
    Assignee: J.M. Huber Corporation
    Inventor: Karl Gallis
  • Patent number: 7438896
    Abstract: Methods for the prevention of skin damage arising from exposure to ultraviolet or solar radiation, using lipoic acid and asorbic acid and/or ascorbic acid derivative in a dermatologically acceptable carrier that can be topically applied to the skin areas. Tocotrienol and/or an ?-hydroxy acid such as glycolic acid is applied with the lipoic acid and ascorbic acid an/or its derivatives in some embodiments.
    Type: Grant
    Filed: June 21, 2004
    Date of Patent: October 21, 2008
    Assignee: N.V. Perricone LLC
    Inventor: Nicholas V. Perricone
  • Patent number: 7438897
    Abstract: The present invention discloses cosmetic transparent hair removal (depilatory) compositions that: (1) Are transparent in appearance, (2) Can be made in cold wax or hot wax forms, (3) Manufactured at much less than 80 ° C., (4) Three-dimensional particles of visually attractive compositions can be added, (5) Bind more strongly with hair and less strongly with skin, (6) Can be applied either directly on the skin or applied on a piece of fabric, plastic, or paper first, which is then applied to skin for hair removal, and (7) Require minimal clean-up.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: October 21, 2008
    Assignee: Bioderm Research
    Inventor: Shyam K. Gupta
  • Patent number: 7438898
    Abstract: Hair conditioning compositions are disclosed comprising: (1) a carboxylic acid/carboxylate copolymer; (2) a visible particle; and (3) an aqueous carrier.
    Type: Grant
    Filed: July 30, 1998
    Date of Patent: October 21, 2008
    Assignee: The Procter & Gamble Company
    Inventors: Takashi Sako, Bruce Russell Cox
  • Patent number: 7438899
    Abstract: The present invention relates to the treatment of gastrointestinal disease and/or cancer, and a method of weight gain, via the ingestion of polymeric compositions in humans, animals or birds in need of said treatment. The invention provides methods for the treatment of cancer, the treatment and/or prevention of gastrointestinal disease and/or infection and/or diarrhoea, and a method for increasing weight gain in humans, animals or birds comprising administering to said humans, animals or birds an effective amount of a pharmaceutical or veterinary composition, or feed additive, comprising an effective amount of a polymer and/or copolymer, having the repeating polymeric unit (I), wherein R is H or alkyl, usually C1 to C4, or this unit in hydrated, hemiacetal or acetal form, together with a pharmaceutically or veterinarally acceptable carrier, diluent, adjuvant, excipient and/or controlled release system.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: October 21, 2008
    Assignee: Chemeq Ltd.
    Inventor: Graham John Hamilton Melrose
  • Patent number: 7438900
    Abstract: A pharmaceutical composition comprising an active agent bound to a scaffold for dendritic encapsulation wherein said scaffold is covalently or non-covalently attached to a polysaccharide. More specifically, the invention is directed to active agent complexes or conjugates which utilize dendritic encapsulation alone or in combination with other delivery systems to improve and target active agent release.
    Type: Grant
    Filed: July 8, 2004
    Date of Patent: October 21, 2008
    Assignee: Shire LLC
    Inventors: Thomas Piccariello, Travis Mickle, Barney Bishop
  • Patent number: 7438901
    Abstract: The present invention relates to virulent (lytic) Listeria monocytogenes phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and/or to the infrastructure of the food processing plants within which such food products are processed, or the containers or wraps in which such foods are stored and/or shipped, in order to reduce Listeria monocytogenes contamination. P100 can also be used in the present invention to identify Listeria monocytogenes bacteria present on (or within) foodstuffs, as well as those Listeria monocytogenes bacteria present in the equipment or the general environment of the food processing plants in which the foodstuffs are being processed and in animals infected with Listeria monocytogenes. The phage and the endolysin of the present invention can also be used to treat animals infected with Listeria monocytogenes.
    Type: Grant
    Filed: July 7, 2003
    Date of Patent: October 21, 2008
    Assignee: Exponential Biotherapies, Inc.
    Inventors: Martin Loessner, Richard M. Carlton
  • Patent number: 7438902
    Abstract: Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: October 21, 2008
    Assignee: The General Hospital Corporation
    Inventors: Joel E. Habener, Henryk Zulewski, Elizabeth J. Abraham, Mario Vallejo, Denise L. Faustman, Melissa K. Thomas
  • Patent number: 7438903
    Abstract: Bioavailability of Coenzyme-Q10 (“Co-Q10”), an oil-soluble substance, can be enhanced in a subject by modifying, e.g. nanonizing or charging, the form of Co-Q10. Co-Q10 bioavailability also can be enhanced by administering Co-Q10 to the subject as an oil (lipid)-based and water (hydro)-based mixed composition, along with other optional components, such as oils, resins and other carriers. Accordingly, the invention provides various Co-Q10 compositions, e.g. compositions comprised of (i) Co-Q10 dissolved in one or more Co-Q10-soluble oils and (ii) Co-Q10 in admixture with at least one water-dispersible agent. A Co-Q10 complex of the invention, therefore, yields an increased cell absorption rate, as well as an enhanced percentage of Co-Q10 peak absorption, compared to previously known compounds. Methods for making and using the aforementioned compositions also are provided.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: October 21, 2008
    Assignee: NBTY, Inc.
    Inventor: Daryoush Parkhideh
  • Patent number: 7438904
    Abstract: A novel computational method and generation of mutant butyrylcholinesterase for cocaine hydrolysis is provided. The method includes molecular modeling a possible BChE mutant and conducting molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations thereby providing a screening method of possible BChE mutants by predicting which mutant will lead to a more stable transition state for a rate determining step. Site-directed mutagenesis, protein expression, and protein activity is conducted for mutants determined computationally as being good candidates for possible BChE mutants, i.e., ones predicted to have higher catalytic efficiency as compared with wild-type BChE. In addition, mutants A199S/A328W/Y332G, A199S/F227A/A328W/Y332G, A199S/S287G/A328W/Y332G, A199S/F227A/S287G/A328W/Y332G, and A199S/F227A/S287G/A328W/E441D all have enhanced catalytic efficiency for (?)-cocaine compared with wild-type BChE.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: October 21, 2008
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Hoon Cho, Hsin-Hsiung Tai
  • Patent number: 7438905
    Abstract: Graft rejection is a serious problem associated with tissue or organ transplantation (e.g., allotransplantation or xenotransplantation), performed to treat various organ failures (e.g., liver, heart, lung, kidney, or pancreas). Described are pharmaceutical compositions for suppressing, treating, or preventing graft rejection comprising a substance having an activity to modulate signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: October 21, 2008
    Assignee: Japan Tobacco, Inc.
    Inventors: Atsuko Suzuki, legal representative, Mitsuaki Isobe, Seiichi Suzuki
  • Patent number: 7438906
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: October 21, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Patent number: 7438907
    Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: October 21, 2008
    Assignee: Genmab A/S
    Inventors: Janine Schuurman, Catharina Emanuele Gerarda Havenith, Paul Parren, Jan G. J. Van De Winkel, Denise Leah Williams, Jørgen Petersen, Ole Baadsgaard
  • Patent number: 7438908
    Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: October 21, 2008
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Rita De Santis, Anna Maria Anastasi
  • Patent number: 7438909
    Abstract: A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and/or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: October 21, 2008
    Assignee: Emergent Product Development Gaithersburg Inc.
    Inventors: Jeanne Morrow, legal representative, Angray S. Kang, Fei Wang, Ivy Jiang, Ritsuko Sawada, Wolfgang Scholz, Phillip R. Morrow
  • Patent number: 7438910
    Abstract: Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: October 21, 2008
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: Brian Varnum, Chris Vezina, Alison Witte, Xueming Qian, Francis Hall Martin, Haichun Huang, Gary Elliott
  • Patent number: 7438911
    Abstract: For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5×109 M?1 or more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: October 21, 2008
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Akiko Furuya, Rinpei Niwa, Yuji Ohki, Nobuo Hanai
  • Patent number: 7438912
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: October 21, 2008
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
  • Patent number: 7438913
    Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R? can be used in medicine, in diagnosis and in screening for agonists/antagonist of IL-13/IL-4. One such polypeptide is shown in FIG. 1.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: October 21, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jean-Yves Bonnefoy, Jean-François Gauchat
  • Patent number: 7438914
    Abstract: A composition and method for enhancing immune response in a living organism is disclosed. In particular, the present disclosure provides an adjuvant peptide for use in raising an immune response to an antigen. The adjuvant peptide is selected from a group of peptides with an HIV-related sequence. Additionally, the adjuvant peptide can comprise a fusion-protein that acts as a mucosal adjuvant. The adjuvant peptide can be transformed into one or more living cells, such that the mucosal adjuvant can be produced in living cells and then administered by systemic, mucosal or epidermal delivery.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: October 21, 2008
    Assignee: Arizona Board of Regents, Acting for and on Behalf of Arizona State University
    Inventors: Tsafrir S. Mor, Nobuyuki Matoba, Charles J. Arntzen
  • Patent number: 7438915
    Abstract: This study reports a novel immunopotentiating effect of a lectin (FFrL) extracted from the mushroom Fomitella fraxinea on poultry cell-mediated immunity and poultry coccidiosis. We describe the extraction of FFrL, its in vitro mitogenic activity and in vivo protection against an oral challenge infection with Eimeria acervulina. When tested on several cell types, crude FFrL agglutinated mouse erythrocytes and thymocytes and also various other cells including murine and human cell lines. However, crude FFrL did not agglutinate human A, B, AB, or O erythrocytes. FFrL showed a potent mitogenic activity on chicken splenic lymphocytes where at lower concentrations, crude FFrL exerted stronger mitogenic activity than Con A, a well-known potent mitogen for T lymphocytes. Further, FFrL significantly induced (P<0.05) nitric oxide secretion in HD11 cells, an established macrophage cell line, and suppressed (P<0.05) RP9 tumor cell growth, both, in a dose-dependent fashion.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: October 21, 2008
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventor: Hyun S. Lillehoj
  • Patent number: 7438916
    Abstract: A novel Fasciclin Related Adhesive Protein (FRAP) from Plasmodium and related parasites is provided as a target for therapeutic intervention in diseases caused by the parasites. FRAP has been shown to play a critical role in adhesion to, or invasion into, host cells by the parasite. Furthermore, FRAP catalyzes the neutralization of heme by the parasite, by promoting its polymerization into hemozoin. This invention provides methods and compositions for therapies based on the administration of protein, DNA or cell-based vaccines and/or antibodies based on FRAP, or antigenic epitopes of FRAP, either alone or in combination with other parasite antigens. Methods for the development of compounds that inhibit the catalytic activity of FRAP, and diagnostic and laboratory methods utilizing FRAP are also provided.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: October 21, 2008
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Dharmendar Rathore, Dewal Jani, Rana Nagarkatti
  • Patent number: 7438917
    Abstract: The present invention relates to an in vitro diagnostic method for malaria in an individual comprising placing a tissue or a biological fluid taken from an individual in contact with a molecule or polypeptide composition, wherein said molecule or polypeptide composition comprises one or more peptide sequences bearing all or part of one or more T epitopes of the proteins resulting from the infectious activity of P. falciparum, under conditions allowing an in vitro immunological reaction to occur between said composition and the antibodies that may be present in the tissue or biological fluid, and in vitro detection of the antigen-antibody complexes formed. The invention further relates to a polypeptide comprising at least one T epitope from a liver-stage specific protein produced by P. falciparum and a vaccine composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of P.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: October 21, 2008
    Assignee: Institut Pasteur
    Inventors: Claudine Guerin-Marchand, Pierre Druilhe
  • Patent number: 7438918
    Abstract: The invention provides lipid A deficient mutant Neisseria meningitidis cells, pharmaceutical compositions incorporating such cells, and methods of using such cells.
    Type: Grant
    Filed: August 29, 2003
    Date of Patent: October 21, 2008
    Assignee: University of Iowa Research Foundation
    Inventors: Michael A. Apicella, Deborah Post
  • Patent number: 7438919
    Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: October 21, 2008
    Assignee: The University of Pittsburgh -- of the Commonwealth System of Higher Education
    Inventors: Patricia W. Dowling, Julius S. Youngner
  • Patent number: 7438920
    Abstract: The invention relates to the X-ray crystal structure of the hepatitis C virus helicase domain. More specifically, the invention relates to crystallized complexes of HCV helicase and an oligonucleotide, to crystallizable compositions of HCV helicase and an oligonucleotide and to methods of crystallizing an HCV helicase-oligonucleotide complex. The invention further relates to a computer programmed with the structure coordinates of the HCV helicase oligonucleotide binding pocket or the HCV helicase nucleotide triphosphate pocket wherein said computer is capable of displaying a three-dimensional representation of that binding pocket.
    Type: Grant
    Filed: April 30, 1999
    Date of Patent: October 21, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Joseph L. Kim, Kurt Morgenstern, Paul Caron, Chao Lin
  • Patent number: 7438921
    Abstract: Methods for treating a buttock deformity or for preventing development of a buttock deformity by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a buttock deformity or to the vicinity of a buttock deformity.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: October 21, 2008
    Assignee: Allergan, Inc.
    Inventor: Eric R. First
  • Patent number: 7438922
    Abstract: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumor specific antigens (“TSAs”) and/or tumor associated antigens (“TAAs”) having shared identity with antigens in a targeted tumor. In such cases, tumor cells often are utilized as a starting point on the premise that only tumor cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalized normal, non-malignant cells, in combination with primary and/or metastatic tumor cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumor cells.
    Type: Grant
    Filed: July 23, 2004
    Date of Patent: October 21, 2008
    Assignee: Onyvax Limited
    Inventors: Angus George Dalgleish, Anthony Ian Walker
  • Patent number: 7438923
    Abstract: Synergistic and residual pesticidal compositions containing synergistic and residual mixtures of plant essential oils in admixture with enzyme inhibitors, with or without other compounds not previously used as active ingredients in pesticidal formulations. In addition, the present invention is directed to a method for controlling pests by applying a pesticidally-effective amount of the above synergistic and residual pesticidal compositions to a locus where pest control is desired.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: October 21, 2008
    Assignee: Ecosmart Technologies, Inc.
    Inventor: Steven M. Bessette
  • Patent number: 7438924
    Abstract: This invention relates to a pharmaceutical formulation, in the form of a tablet, sachet or powder for suspension dosage form, which comprises dry granulated particles of a non-dihydrate form of azithromycin and, optionally, one or more pharmaceutically acceptable excipients. Preferably, the pharmaceutical formulation is a tablet containing between about 40%, by weight, to about 90%, by weight, non-dihydrate azithromycin. More preferably, the pharmaceutical formulation contains non-dihydrate azithromycin selected from the forms B, D, E, F, G, H, J, M, N, O, P, Q, R, or mixtures thereof. Even more preferably, the invention relates to a pharmaceutical formulation wherein the dosage of azithromycin is 250 mgA, 500 mgA, 600 mgA or 1000 mgA. The present invention further relates to a dry granulated azithromycin particle, comprising a form of azithromycin, selected from forms D, E, F, G, H, J, M, N, O, P, Q, R and mixtures of non-dihydrate forms, and at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: October 21, 2008
    Assignee: Pfizer Inc
    Inventors: Barbara A. Johnson, Ernest S. Quan
  • Patent number: 7438925
    Abstract: Drug eluting coating compositions are composed of at least one therapeutic agent dispersed in modified, biologically active binders. The therapeutic agents included in the coating composition are paclitaxel, sirolimus, tacrolimus, everolimus, actinomycin-D, dexamethasone, mycophenolic acid, cyclosporins, estradiol, and derivatives and analogs thereof. These therapeutic agents are applied to the surface of the medical device by a modified, biologically active binders. By using these biologically active binders, the therapeutic agents can be applied to at least one surface of a medical implant without using inert polymer carriers.
    Type: Grant
    Filed: April 26, 2003
    Date of Patent: October 21, 2008
    Assignee: Biovention Holdings Ltd.
    Inventor: Li-Chien Hsu
  • Patent number: 7438926
    Abstract: This invention relates to a method for inhibiting a decrease in the transdermal flux of an agent that is being transdermally delivered or sampled over a prolonged period of time wherein the delivery or sampling involves disrupting at least the stratum corneum layer of the skin to form pathways through which the agent passes. The desired result is achieved by co-delivering or co-sampling the agent with an amount of at least one anti-healing agent wherein the amount of the anti-healing agent is effective in inhibiting a decrease in the agent transdermal flux compared to when the delivery or sampling of the agent is done under substantially identical conditions except in the absence of the anti-healing agent(s).
    Type: Grant
    Filed: September 8, 2001
    Date of Patent: October 21, 2008
    Assignee: Alza Corporation
    Inventors: Michel Cormier, Juanita Johnson, Wei Qi Lin, James Matriano, Peter Daddona
  • Patent number: 7438927
    Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: October 21, 2008
    Assignee: Depomed, Inc.
    Inventors: Bret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
  • Patent number: 7438928
    Abstract: A topical gel matrix that can be used alone or combination with a medication entrapped therein. The gel matrix is dispersible in water. The gel may have the following composition: oil, water or aqueous solution; solvents, surfactants and/or detergents; and a polymer which is a consistence modifier capable of thickening and to resist degradation in a water environment. The matrix may comprise or not a biologically active ingredient for a systemic or topical indication. Amongst preferred medications are anaesthetic, anti-histaminic, anti-inflammatory, anti-oxidant, anti-UVs, anti-microbial and wound healing agents. More specifically, for the treatment of fish infections, examples of preferred active ingredients are natural or synthetic plants extracts.
    Type: Grant
    Filed: October 15, 2003
    Date of Patent: October 21, 2008
    Assignee: Rolf C. Hagen, Inc.
    Inventors: Anthony Costa, Benoit Choquet, Yvan Giguère
  • Patent number: 7438929
    Abstract: The invention relates to a multiparticulate drug form suitable for uniform release of an active pharmaceutical ingredient in the small intestine and in the large intestine, comprising at least two forms of pellets A and B which comprise an active pharmaceutical ingredient in the core and have different polymer coatings which determine the release of the active ingredient at different pH values, characterized in that pellet form A is provided with an inner polymer coating which enables continuous release of active ingredient, and has an outer enteric coating which rapidly dissolves above about pH 5.5, and pellet form B is provided with a polymer coating which, in the USP release test, releases less than 20% of the active ingredient at pH 6.8 in 6 hours and releases more than 50% of the active ingredient at pH 7.2 in 6 hours. The invention additionally relates to a process for producing the multiparticulate drug form and to the use of pellet forms A and B for producing the drug form.
    Type: Grant
    Filed: September 27, 2004
    Date of Patent: October 21, 2008
    Assignee: Roehm GmbH & Co. KG
    Inventors: Thomas Beckert, Hans-Ulrich Petereit, Jennifer Dressman, Markus Rudolph
  • Patent number: 7438930
    Abstract: The invention is directed to oral modified/controlled release drug formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak concentration is lower than that provided by the reference standard for immediate release formulations of the drug, and the duration of effect falls rapidly at the end of the dosing interval.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: October 21, 2008
    Assignee: Purdue Pharma
    Inventors: Thinnayam N. Krishnamurthy, Andrew Darke
  • Patent number: 7438931
    Abstract: Provided are agents that can bind to copper, and form a tripartite complex with protein, and the use of these agents in the prevention and treatment of diseases with a vascular component, such as solid tumors. Compositions and methods for combination therapy of these diseases, including cancer, as well as therapeutic kits, are also provided.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: October 21, 2008
    Assignee: The Regents of The University of Michigan
    Inventors: George J. Brewer, Sofia D. Merajver, Dimitri Coucouvanis
  • Patent number: 7438932
    Abstract: The invention provides a method for treating stomach discomfort, stomachache, intestinal discomfort, gastric ulcer, duodenal ulcer or diarrhea by administration of extracts of Utleria solicifolia, Asparagus racemosus, Foeniculum vulgare, and Ficus glomerata.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: October 21, 2008
    Assignee: Council of Scientific and Industrial Research
    Inventors: Pushpangadan Palpu, Rao Chandana Venkateswara, Govindarajan Raghavan, Mehrotra Shanta, Radhakrishnan Krishnan Nair
  • Patent number: 7438933
    Abstract: The present invention provides uses of multi-nutrient supplements to rescue aberrant biochemical pathways and reduce birth defect caused by maternal diabetes. Choice of supplements is based on the ability of each supplement to correct the following hyperglycemia-associated abnormalities: increased reactive oxygen species generation, abnormal membrane phospholipid metabolism, and decreased glutathione synthesis.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: October 21, 2008
    Assignee: The Board of Trustees of the University of Arkansas System
    Inventors: YingKing Wu, E. Albert Reece
  • Patent number: 7438934
    Abstract: Pharmaceutical compositions containing: extracts of Tribulus terrestris, Epimedium koreanum, Cinnamon cassia in the weight ratio of 1.5-3.5:1-2:0.1-0.4 respectively; and optionally arginine or a physiologically equivalent ester, salt or precursor thereof. The compositions are useful in the treatment of male and female sexual dysfunctions. A method of treatment using the pharmaceutical compositions is also described.
    Type: Grant
    Filed: February 25, 2008
    Date of Patent: October 21, 2008
    Assignee: Indena S.p.A.
    Inventors: Ezio Bombardelli, Paolo Morazzoni, Antonella Riva, Roberto Seghizzi
  • Patent number: 7438935
    Abstract: The present invention discloses a pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases which comprises Radix Salviae Miltiorrhizae extract 5.0%-70.0%, Radix Notoginseng extract 10.0%-85.0%, Radix Astragali extract 5.0%-70.0%, and Bomeol or oil of Lignum Dalbergiae Odoriferae 1.0%-15.0%. The composition is active against cerebral ischemia and myocardial ischemia. The effects are superior to total phenic acid of Radix Salviae Miltiorrhizae or total saponin of Radix Notoginseng respectively, or the combination thereof. The composition of the invention can provide various kinds of preparations by the addition of various accessories. Thus the invention provides a more effective and convenient composition of TCM effective sections and its preparations.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: October 21, 2008
    Assignee: Tianjin Tasly Pharmaceutical Co., Ltd.
    Inventors: Feng Wei, Dekun Li, Chongnian Luo, Hongshui Yue, Qingchuang Chen, Zhijuan Huang